1.Using proper APA formatting, cite the peer-reviewed article you selected that pertains to your practice area and is of particular interest to you and identify the database that you used to search for the article.
2.Explain any difficulties you experienced while searching for this article.
3.Would this database(Walden Library and Google Scholar) be useful to your colleagues? Explain why or why not. Would you recommend this database? Explain why or why not.
Attached is the article needed.
You can use any other research platform just specify which one you used. PLEASE FOLLOW THE INSTRUCTIONS LISTED ABOVE. IF YOU HVE ANY QUESTIONS REACH OUT TO ME. THANK YOU.
Title:
Update on Neurodegenerative Diseases and Glutamate: A PMHNP Single Case Study Report of a Diagnostically Complex Adult Patient, Interventions, and Unexpected Outcomes.
Authors:
Kroll SC; Sherri Cofield Kroll, MSN, APRN, FNP-BC, PMHNP-BC, CARN-AP, Outpatient Private Practice PMHNP, Deuser & Associates, PC, Brunswick, GA, USA.
Bennett CF; Carole Frances Bennett, PhD, APRN, PMHCS-BC, Georgia Southern University, Statesboro, GA, USA.
Klinefelter TW; Tarah Winter Klinefelter, MSN, APRN, PMHNP-BC, Psychiatric Mental Health Nurse Practitioner in Geriatric Psychiatry, El Paso, TX, USA.
Source:
Journal of the American Psychiatric Nurses Association [J Am Psychiatr Nurses Assoc] 2021 Jul 08, pp. 10783903211030343. Date of Electronic Publication: 2021 Jul 08.
Objective: While dysfunction of serotonin and dopamine neurotransmitters has been studied in depth, in regard to the etiology of mental illness, the neurotransmitter glutamate and its dysfunction is now being explored as contributing to neurodegenerative psychiatric diseases, schizophrenia, autism, depression, and Alzheimer’s disease. This article explains its synthesis, neurotransmission, and metabolism within the brain and subsequent dysfunction that is responsible for neurocognitive loss associated with several psychiatric disorders.
Method: The case study will report on the screening for pseudobulbar affective (PBA) disorder in a 29-year-old male with bipolar disorder, autism spectrum disorder, and intellectual developmental disability who was experiencing extreme, uncontrolled emotional outbursts requiring continuous family isolation (pre-COVID-19) for safety. With the positive screen for PBA, the patient was subsequently treated with a glutamatergic drug, dextromethorphan/quinidine.
Results: The patient’s unexpected response to this treatment including the acquisition of language, increased cognition, and improved executive functioning is presented. At 2 years post the initiation of treatment, his PBA screening score is reduced, uncontrolled outbursts and aggression have subsided, and the family can spend time outside of their home.
Conclusions: Neurodegeneration and its impact is being researched and treated with medications affecting glutamate. The addition of a glutamatergic medication to this young man’s medication regimen has improved both his and his family’s quality of life. The psychiatric diagnoses, medications, and treatments associated with glutamate are explained in depth. The importance of nurses’ understanding of glutamate, its synthesis, transmission, and dysfunction causing excitotoxicity and brain cell death and its impact on patients’ behavior and safety is explained.
Contributed Indexing:
Keywords: glutamatergic dysfunction; neurocognitive degeneration; severe chronic psychiatric illness
Entry Date(s):
Date Created: 20210709 Latest Revision: 20210709
Update Code:
20220301
DOI:
10.1177/10783903211030343
PMID:
34238041
Persistent link to this record (Permalink):
Cut and Paste:
<A href=”https://search.ebscohost.com/login.aspx?direct=true&AuthType=shib&db=mnh&AN=34238041&site=eds-live&scope=site&custid=s6527200″>Update on Neurodegenerative Diseases and Glutamate: A PMHNP Single Case Study Report of a Diagnostically Complex Adult Patient, Interventions, and Unexpected Outcomes.</A>
Database:
